Jack Mitchell, Director of Health Policy, on behalf of Cancer Prevention and Treatment Fund July 14, 2017 The Senate’s revised health bill was revealed on July 13, 2017. Unfortunately, the revised Better Care Reconciliation Act of 2017 will result in much worse, not better, health care for Americans than our current healthcare program. Tell me […]
July 12, 2017. Given the research design, only one pivotal study, the lack of U.S. patients, and a less than convincing literature review, the data do not support sufficient support for approval. The studies, in our view, do not provide strong evidence that GO is effective and there are still continuing safety concerns.
This is no joke. The Congressional Budget Office’s report only makes it clearer that the Senate health bill will not result in better health care for Americans.
June 21, 2017. Thank you for the opportunity to speak today. My name is Dr. Megan Polanin. I am a Senior Fellow at the National Center for Health Research, and I previously trained at Johns Hopkins University School of Medicine. Our research center analyzes scientific and medical data and provides objective health information to patients, providers, and policymakers. We do not accept funding from pharmaceutical companies, and therefore I have no conflicts of interest.
June 15, 2017. Thank you to the FDA and the Safe Use Team for hosting this meeting and for the opportunity to share our perspective. I’m Dr. Megan Polanin, and I am a Senior Fellow at the National Center for Health Research.
May 24, 2017. The FDA should be sure that new treatments provide a real benefit to patients before they are approved. We recommend that the FDA not approve neratinib for breast cancer unless a clear benefit can be replicated, or a benefit for overall survival is demonstrated.